S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Freshworks gets juiced on its AI customer engagement platform
3 tech outperformers adored by analysts
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
High short interest stocks: this popular trend is re-emerging
Boeing glides past series of setbacks on new flight path
New CBOE “special perk” helps traders target income every weekend (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Freshworks gets juiced on its AI customer engagement platform
3 tech outperformers adored by analysts
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
High short interest stocks: this popular trend is re-emerging
Boeing glides past series of setbacks on new flight path
New CBOE “special perk” helps traders target income every weekend (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Freshworks gets juiced on its AI customer engagement platform
3 tech outperformers adored by analysts
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
High short interest stocks: this popular trend is re-emerging
Boeing glides past series of setbacks on new flight path
New CBOE “special perk” helps traders target income every weekend (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Freshworks gets juiced on its AI customer engagement platform
3 tech outperformers adored by analysts
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
High short interest stocks: this popular trend is re-emerging
Boeing glides past series of setbacks on new flight path
New CBOE “special perk” helps traders target income every weekend (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it

AtriCure (ATRC) Stock Price, News & Analysis

$34.14
+0.70 (+2.09%)
(As of 12/8/2023 08:56 PM ET)
Compare
Today's Range
$32.95
$34.46
50-Day Range
$32.99
$43.25
52-Week Range
$32.27
$59.61
Volume
600,100 shs
Average Volume
354,846 shs
Market Capitalization
$1.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.13

AtriCure MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
76.1% Upside
$60.13 Price Target
Short Interest
Bearish
3.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of AtriCure in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$42,969 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.76) to ($0.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

673rd out of 942 stocks

Surgical & Medical Instruments Industry

65th out of 94 stocks


ATRC stock logo

About AtriCure Stock (NASDAQ:ATRC)

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Stock Price History

ATRC Stock News Headlines

Oppenheimer Keeps Their Hold Rating on Atricure (ATRC)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
AtriCure, Inc. (NASDAQ:ATRC) Short Interest Up 18.2% in November
Where AtriCure Stands With Analysts
The Battery Metal Nobody Told You About
According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."
Buying These 4 Hated Names Devastated By The GLP-1 Hype
AtriCure Releases 2023 ESG Report
AtriCure: Appeal Lures For This Cure
Stifel Nicolaus Reaffirms Their Buy Rating on Atricure (ATRC)
Q3 2023 AtriCure Inc Earnings Call
AtriCure: Q3 Earnings Snapshot
AtriCure Reports Third Quarter 2023 Financial Results
AtriCure earnings: here's what Wall Street expects
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/20/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
1,050
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$60.13
High Stock Price Target
$74.00
Low Stock Price Target
$49.00
Potential Upside/Downside
+76.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-46,470,000.00
Pretax Margin
-6.43%

Debt

Sales & Book Value

Annual Sales
$330.38 million
Book Value
$9.82 per share

Miscellaneous

Free Float
45,973,000
Market Cap
$1.62 billion
Optionable
Optionable
Beta
1.35

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report














ATRC Stock Analysis - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price target for 2024?

7 equities research analysts have issued 12-month price targets for AtriCure's shares. Their ATRC share price targets range from $49.00 to $74.00. On average, they anticipate the company's share price to reach $60.13 in the next twelve months. This suggests a possible upside of 76.1% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2023?

AtriCure's stock was trading at $44.38 at the beginning of 2023. Since then, ATRC shares have decreased by 23.1% and is now trading at $34.14.
View the best growth stocks for 2023 here
.

Are investors shorting AtriCure?

AtriCure saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,620,000 shares, an increase of 18.2% from the October 31st total of 1,370,000 shares. Based on an average daily volume of 356,500 shares, the days-to-cover ratio is presently 4.5 days.
View AtriCure's Short Interest
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our ATRC earnings forecast
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings results on Wednesday, November, 1st. The medical device company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. The medical device company earned $98.29 million during the quarter, compared to analysts' expectations of $96.65 million. AtriCure had a negative net margin of 6.52% and a negative trailing twelve-month return on equity of 6.37%. The company's quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.27) EPS.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?
Who are AtriCure's major shareholders?

AtriCure's stock is owned by many different retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (3.03%), Wellington Management Group LLP (2.60%), Invesco Ltd. (2.18%), TimesSquare Capital Management LLC (1.91%), Loomis Sayles & Co. L P (1.82%) and Fiera Capital Corp (1.45%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does AtriCure have any subsidiaries?
The following companies are subsidiares of AtriCure: SentreHEART.
Read More
This page (NASDAQ:ATRC) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -